retatrutide phase 3 2025 triple agonist glp-1 gip glucagon Today, we shared new data from two trials of retatrutide, our investigational agonist. Learn more: https://go.lilly.com/msrz1v retatrutide phase 3 2025 triple

L- ,

Orforglipron is not suitable for you if you: Are pregnant or breastfeeding Have a personal or family history of a rare type of thyroid cancer called medullary thyroid carcinoma Have a history of multiple endocrine neoplasia syndrome type 2 (MEN 2) Have had inflammation of your pancreas (pancreatitis) in the past Have certain gastrointestinal diseases How to take orforglipron Always take any medicine exactly as your doctor tells you to

For cognitive benefits like sharper focus, it might take a bit longer as your body adapts to the therapy

Treating a peptide like a beauty supplement is how people miss real risks

The international journal of biochemistry & cell biology , 37 (8), 17271737

5